Loading...
Market
Market share of Dupixent in COPD treatment by end of 2024?
2
Resolution / Starting Odds
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Industry reports on market share
Story
Sanofi and Regeneron’s Dupixent Approved for COPD, 'Smoker's Lungs,' in EU
Jul 3, 2024, 05:15 AM
Sanofi and its partner Regeneron have received European Union approval on Wednesday for the expanded use of their Dupixent injection to treat patients with chronic obstructive pulmonary disease (COPD). This marks the first-ever targeted therapy for COPD, also referred to as 'smoker's lungs,' approved in the EU. Notably, the EU's approval process for Dupixent was faster than that of the United States, highlighting a rare instance of expedited clearance. The approval is expected to create a new growth avenue for the blockbuster drug.
View original story
Similar markets
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
0-10% • 25%
10-20% • 25%
20-30% • 25%
30% or more • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 20% • 25%
More than 20% • 25%